Drugs

Aminoglycoside Adaptive Resistance: Importance for Effective Dosage Regimens
pp. 713-721(9)
Authors: Barclay M.L.; Begg E.J.

Farnesyltransferase Inhibitors: Potential Role in the Treatment of Cancer
pp. 723-732(10)
Author: Cox A.D.

Renoprotective Therapy in Patients With Nondiabetic Nephropathies
pp. 733-745(13)
Authors: Pisoni R.; Ruggenenti P.; Remuzzi G.

Fluoroquinolones: Place in Ocular Therapy
pp. 747-761(15)
Authors: Smith A.; Pennefather P.M.; Kaye S.B.; Hart C.A.

Management of Antimicrobial Use in the Intensive Care Unit
pp. 763-775(13)
Authors: Álvarez-Lerma F.; Palomar M.; Grau S.

Thalidomide in Gastrointestinal Disorders
pp. 777-787(11)
Authors: Bousvaros A.; Mueller B.

Desloratadine
pp. 789-796(8)
Authors: McClellan K.; Jarvis B.

Desloratadine: A Viewpoint by James H. Day and Elizabeth Rafeiro
pp. 797-797(1)
Authors: Day J.H.; Rafeiro E.

Desloratadine: A Viewpoint by David I. Bernstein
pp. 797-797(1)
Author: Bernstein D.I.

Zoledronic Acid
pp. 799-805(7)
Authors: Cheer S.M.; Noble S.

Zoledronic Acid: A Viewpoint by Jean-Jacques Body
pp. 806-806(1)
Author: Body J-J.

Zoledronic Acid: A Viewpoint by Allan Lipton
pp. 806-806(1)
Author: Lipton A.

Fulvestrant
pp. 807-813(7)
Authors: Curran M.; Wiseman L.

Fulvestrant: A Viewpoint by Robert W. Carlson
pp. 814-814(1)
Author: Carlson R.W.

Fulvestrant: A Viewpoint by Roger W. Blamey
pp. 814-814(1)
Author: Blamey R.W.

Telithromycin
pp. 815-829(15)
Authors: Barman Balfour J.A.; Figgitt D.P.

Telithromycin: A Viewpoint by S. Ragnar Norrby
pp. 830-831(2)
Author: Norrby S.R.

Telithromycin: A Viewpoint by Arthur L. Barry
pp. 830-831(2)
Author: Barry A.L.

Rofecoxib: A Review of its Use in the Management of Osteoarthritis, Acute Pain and Rheumatoid Arthritis
pp. 833-865(33)
Authors: Matheson A.J.; Figgitt D.P.

Perindopril: An Updated Review of Its Use in Hypertension
pp. 867-896(30)
Authors: Hurst M.; Jarvis B.